GLP-1 Analogues Market to Reach USD 211.8 Bn by 2035 Amid Rising Diabetes and Obesity Cases |TMR
GLP-1 Analogues Market
Market growth is driven by rising type 2 diabetes and obesity, an aging population, lifestyle changes, and new drug innovations.
Growing Aging Population and Lifestyle Shifts Propel GLP-1 Analogues Market at 13.7% CAGR”
WILMINGTON, DE, UNITED STATES, February 25, 2026 /EINPresswire.com/ -- The global GLP-1 analogues market was valued at USD 51.6 Bn in 2024 and is projected to surge to USD 211.8 Bn by 2035, registering a robust CAGR of 13.7% during 2025β2035. Market growth is primarily fueled by the rising prevalence of type 2 diabetes and obesity worldwide, along with an expanding aging population and increasingly sedentary lifestyles. Additionally, continuous advancements in innovative and improved drug formulations are further accelerating the adoption of GLP-1 analogues, supporting strong long-term market expansion.— Transparency Market Research Inc.
π Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86893
Market Overview
GLP-1 analogues or GLP-1 receptor agonists refer to a class of medication that mimics the activity of the endogenous incretin hormone GLP-1, responsible for the stimulation of insulin secretion, inhibition of glucagon release, and regulation of blood glucose. The analogues provide glucose regulation through stimulation of the GLP-1 receptors.
In addition to glucose regulation, GLP-1 analogues have additional metabolic actions. They block gastric emptying, decrease appetite, and reduce weight, which makes them particularly profitable in type 2 diabetic patients and obese patients. Their cardiovascular value, evident in clinical trials, has also expanded their usage in cardiovascular morbidity.
Their mode of action is inclusive of increasingthe release of insulin in a glucose-dependent manner, thereby lowering the risk of hypoglycemia as compared to the other anti-diabetic agents. Additionally, these agents improve pancreatic Ξ²-cell function and become a means of achieving better long-term metabolic control, thereby making them a key part of modern approaches to diabetes management.
Analysts' Viewpoint on the Global GLP-1 Analogues Market
GLP-1 analogues market is driven by strong clinical evidence demonstrating benefits to the cardiovascular and metabolic systems, growing healthcare spending, and extended reimbursement plans that further enhance patient access. Moreover, enhanced physician confidence and guideline support for wider therapeutic applications propel earlier adoption in a large number of healthcare facilities and payer systems, worldwide.
Another key driver is the diversification of therapeutic area, i.e., obesity and management of cardio metabolic risk to expand market opportunity. Increased scale of manufacturing, efficient cold-chain logistics, and increasing investments by biopharma stakeholders reduces unit cost and increases geographic presence, especially into previously underpenetrated emerging markets, thus, solidifying clinical partnerships and distribution networks.
The ongoing trends include a growing use of oral formulations of GLP-1 together with long-acting injectables, integration of digital health tools for adherence, and a focused approach to real-world evidence studies that provide long-term outcomes. Payers increasingly use value-based contracting and stepwise access models that impact formulary placement and commercial strategies across markets, together with personalized patient engagement.
Analysis of Key Players in the GLP-1 Analogues Market
The market is a high-stakes "Duopoly" currently expanding into a broader competitive landscape.
Leading companies include:
β’ Novo Nordisk A/S: The pioneer, dominating with the semaglutide franchise. In January 2026, it launched the Wegovy pill, a critical move to maintain its lead in the oral segment.
β’ Eli Lilly and Company: Currently challenging for the top spot with tirzepatide. Its "LillyDirect" platform has revolutionized the industry by shipping medications directly to patients' homes.
β’ AstraZeneca: Focusing on oral small-molecule GLP-1s and combinations for chronic kidney disease.
β’ Pfizer Inc.: Making a major 2026 push via a US$ 495 Mn deal to market ecnoglutide (a next-gen injectable) in China.
β’ Structure Therapeutics & Viking Therapeutics: High-growth "disruptors" focusing on oral, non-peptide GLP-1s that promise fewer side effects and easier manufacturing.
Recent Developments in GLP-1 Analogues Market
β’ In October 2025, Novo Nordisk A/S announced that the company obtained U.S. Food and Drug Administration (FDA) approval for Rybelsus in the treatment of type 2 diabetes patients who are at risk of the major adverse cardiovascular events (MACE), such as heart attack, stroke, or cardiovascular death. The authorization was based on the outcome of the SOUL clinical trial.
β’ In August 2025, Teva Pharmaceutical Industries Ltd announced that the company received U.S. FDA approval for its generic version of Saxenda (liraglutide injection), indication for weight loss.
π Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=86893
Key Developments in the GLP-1 Market
β’ Dual & Tri-Agonists: Move toward drugs that hit multiple receptors (GLP-1, GIP, and Glucagon) to maximize weight loss while preserving lean muscle.
β’ Direct-to-Consumer (DTC) Pharmacy: The rise of manufacturer-led home delivery (NovoCare, LillyDirect) bypassing traditional retail pharmacies.
β’ Muscle-Sparing Formulations: New research into "G-Actin" combinations to ensure weight loss is fat-heavy, not muscle-heavy.
β’ Biosimilar Surge: The first wave of high-quality semaglutide biosimilars hitting markets in Brazil and India in Q1 2026.
Key Player Strategies
β’ π Manufacturing Sovereignty: Investing billions in "fill-finish" sites (e.g., Novo's acquisition of Catalent sites) to control the entire supply chain.
β’ π§ Indication Expansion: Aggressively pursuing approvals for Sleep Apnea and Parkinsonβs to secure long-term reimbursement.
β’ π Emerging Market Pricing: Implementing tiered pricing models in SE Asia and Latin America to capture volume in regions with rising metabolic disease.
β’ π Food Industry Alliances: Partnering with nutrition companies to create specialized shakes and supplements for GLP-1 "maintenance" phases.
Challenges
β’ Reimbursement Hurdles: High monthly costs (US$ 900β1,300) are causing insurers to implement strict "prior authorization" rules.
β’ Long-Term Adherence: "GLP-1 Fatigue"βnearly 50% of patients discontinue use within a year due to cost or GI side effects.
β’ Compounding & Counterfeits: The rise of unauthorized "research grade" peptides sold online, posing significant safety risks.
Market Segmentation
β€ By Product
β’ Semaglutide (Ozempic, Wegovy, Rybelsus)
β’ Tirzepatide (Mounjaro, Zepbound)
β’ Dulaglutide (Trulicity) β Fading segment
β’ Next-Gen Molecules (Orforglipron, Retatrutide, CagriSema)
β€ By Route of Administration
β’ Subcutaneous Injection (75% share in 2026)
β’ Oral Tablets (Fastest growing segment)
β€ By Application
β’ Type 2 Diabetes (Current volume leader)
β’ Obesity & Weight Management (Projected value leader)
β’ Cardiovascular & Other Indications (Emerging)
β€ By Region
β’ North America
β’ Europe
β’ Asia Pacific
β’ Latin America
β’ Middle East & Africa
π To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86893<ype=S
Frequently Asked Questions
β’ How big was the global GLP-1 analogues market in 2024?
The global GLP-1 analogues market was valued at US$ 51.6 Bn in 2024
β’ How big will the global GLP-1 analogues industry be in 2035?
The global GLP-1 analogues industry is projected to reach more than US$ 211.8 Bn by the end of 2035
β’ What are the factors driving the GLP-1 analogues market?
The rising prevalence of type 2 diabetes and obesity, rising aging populations and lifestyle changes, development of new and improved formulations, such as oral and multi-agonist therapies, and the increasing awareness regarding dual benefits of GLP-1 analogues for glycemic control and weight loss are some of the factors driving the expansion of GLP-1 analogues market.
β’ What will be the CAGR of the global GLP-1 analogues industry during the forecast period?
The CAGR is anticipated to be 13.7% from 2025 to 2035
More Trending Research Reports-
Osteoporosis Drugs Market - https://www.transparencymarketresearch.com/osteoporosis-drug-market.html
Anti-Venom Market - https://www.transparencymarketresearch.com/anti-venom-market.html
Psychotropic Drugs Market - https://www.transparencymarketresearch.com/psychotropic-drugs-market.html
CAR T-cell Therapy Market - https://www.transparencymarketresearch.com/car-t-cell-therapy-market.html
Non-Small Cell Lung Cancer Therapeutics Market - https://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA β Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Abhishek Budholiya - Marketing Team
Transparency Market Research Inc.
+1 518-618-1030
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
